Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

6.32USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$6.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
184,217
52-wk High
$25.95
52-wk Low
$5.42

ZYNE.OQ

Chart for ZYNE.OQ

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $84.32
Shares Outstanding(Mil.): 13.26
Dividend: --
Yield (%): --

Financials

BRIEF-Zynerba Pharmaceuticals announces results from phase 2 STOP clinical trial

* Zynerba Pharmaceuticals announces that results from phase 2 stop trial support continued development of ZYN002 in osteoarthritis

14 Aug 2017

Zynerba shares plunge as cannabis-based epilepsy gel fails study

Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

07 Aug 2017

UPDATE 2-Zynerba shares plunge as cannabis-based epilepsy gel fails study

* ZYNE stock sinks about 60 pct, GW shares rise 4 pct (Adds analysts' comments, conf. call details, GW shares; updates ZYNE shares)

07 Aug 2017

Zynerba's cannabis-based gel for epilepsy fails study

Aug 7 Zynerba Pharmaceuticals said on Monday its experimental synthetic cannabis-based gel failed to induce a statistically significant reduction in seizures in a mid-stage study involving epilepsy patients.

07 Aug 2017

BRIEF-Zynerba Pharma announces top-line results from phase 2 star 1 trial of ZYN002

* Zynerba Pharmaceuticals announces top-line results from phase 2 star 1 trial of ZYN002 in adult epilepsy patients with focal seizures

07 Aug 2017

BRIEF-Zynerba Pharmaceuticals reports second quarter 2017 results

* Zynerba Pharmaceuticals reports second quarter 2017 financial results and operational highlights

01 Aug 2017

BRIEF-Zynerba Pharmaceuticals initiates ZYN001 phase 1 clinical program

* Zynerba Pharmaceuticals initiates ZYN001 phase 1 clinical program

26 Jun 2017

BRIEF-Zynerba Pharma achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome

* Zynerba Pharmaceuticals achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome Source text for Eikon: Further company coverage:

08 Jun 2017

BRIEF-Zynerba Pharmaceuticals reports Q1 loss per share $0.60

* Zynerba Pharmaceuticals reports first quarter 2017 financial results and operational highlights

09 May 2017

BRIEF-Zynerba Pharmaceuticals qtrly loss per share $0.71

* Zynerba - top-line results from fab-c exploratory phase 2 clinical trial in pediatric patients with fragile x syndrome expected in q3 of 2017

27 Mar 2017

Earnings vs. Estimates